Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Patent News

Novel Arcyriaflavin-A Derivatives as PIM Kinase Inhibitors for Treating Cancer

Author(s): Surya K. De*

Volume 23, Issue 14, 2023

Published on: 01 June, 2023

Page: [1697 - 1700] Pages: 4

DOI: 10.2174/1871520623666230508101745

Price: $65

Abstract

The present application reports a series of novel Arcyriaflavin-A derivatives as PIM kinase inhibitors for the effective treatment of cancer. The application also describes the synthesis of compounds in detail, use, pharmaceutical composition, pharmaceutically acceptable salts, and treatment.

« Previous
Graphical Abstract

[1]
Walhekar, V.; Bagul, C.; Kumar, D.; Muthal, A.; Achaiah, G.; Kulkarni, R. Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. Biochim. Biophys. Acta Rev. Cancer, 2022, 1877(3), 188725.
[http://dx.doi.org/10.1016/j.bbcan.2022.188725] [PMID: 35367531]
[2]
Rathi, A.; Kumar, D.; Hasan, G.M.; Haque, M.M.; Hassan, M.I. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochim. Biophys. Acta, Gen. Subj., 2021, 1865(11), 129995.
[http://dx.doi.org/10.1016/j.bbagen.2021.129995] [PMID: 34455019]
[3]
Panchal, N.K.; Sabina, E.P. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. Life Sci., 2020, 255, 117866.
[http://dx.doi.org/10.1016/j.lfs.2020.117866] [PMID: 32479955]
[4]
Asati, V.; Mahapatra, D.K.; Bharti, S.K. PIM kinase inhibitors: Structural and pharmacological perspectives. Eur. J. Med. Chem., 2019, 172, 95-108.
[http://dx.doi.org/10.1016/j.ejmech.2019.03.050] [PMID: 30954777]
[5]
Le, B.T.; Kumarasiri, M.; Adams, J.R.J.; Yu, M.; Milne, R.; Sykes, M.J.; Wang, S. Targeting Pim kinases for cancer treatment: Opportunities and challenges. Future Med. Chem., 2015, 7(1), 35-53.
[http://dx.doi.org/10.4155/fmc.14.145] [PMID: 25582332]
[6]
Swords, R.; Kelly, K.; Carew, J.; Nawrocki, S.; Mahalingam, D.; Sarantopoulos, J.; Bearss, D.; Giles, F. The Pim kinases: New targets for drug development. Curr. Drug Targets, 2011, 12(14), 2059-2066.
[http://dx.doi.org/10.2174/138945011798829447] [PMID: 21777193]
[7]
Nawijn, M.C.; Alendar, A.; Berns, A. For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer, 2011, 11(1), 23-34.
[http://dx.doi.org/10.1038/nrc2986] [PMID: 21150935]
[8]
Anizon, F.; Shtil, A.A.; Danilenko, V.N.; Moreau, P. Fighting tumor cell survival: Advances in the design and evaluation of Pim inhibitors. Curr. Med. Chem., 2010, 17(34), 4114-4133.
[http://dx.doi.org/10.2174/092986710793348554] [PMID: 20939820]
[9]
Qin, R.; You, F.M.; Zhao, Q.; Xie, X.; Peng, C.; Zhan, G.; Han, B. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: From molecular mechanisms to potential therapeutic targets. J. Hematol. Oncol., 2022, 15(1), 133.
[http://dx.doi.org/10.1186/s13045-022-01350-z] [PMID: 36104717]
[10]
Gotlib, J.; Kluin-Nelemans, H.C.; George, T.I.; Akin, C.; Sotlar, K.; Hermine, O.; Awan, F.T.; Hexner, E.; Mauro, M.J.; Sternberg, D.W.; Villeneuve, M.; Huntsman Labed, A.; Stanek, E.J.; Hartmann, K.; Horny, H.P.; Valent, P.; Reiter, A. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl. J. Med., 2016, 374(26), 2530-2541.
[http://dx.doi.org/10.1056/NEJMoa1513098] [PMID: 27355533]
[11]
Stone, R.M.; Mandrekar, S.J.; Sanford, B.L.; Laumann, K.; Geyer, S.; Bloomfield, C.D.; Thiede, C.; Prior, T.W.; Döhner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R.B.; Wei, A.; Sierra, J.; Sanz, M.A.; Brandwein, J.M.; de Witte, T.; Niederwieser, D.; Appelbaum, F.R.; Medeiros, B.C.; Tallman, M.S.; Krauter, J.; Schlenk, R.F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R.A.; Döhner, H. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med., 2017, 377(5), 454-464.
[http://dx.doi.org/10.1056/NEJMoa1614359] [PMID: 28644114]
[12]
Theoharides, T.C.; Valent, P.; Akin, C. Mast cells, mastocytosis, and related disorders. N. Engl. J. Med., 2015, 373(19), 1884-1886.
[http://dx.doi.org/10.1056/NEJMc1510021] [PMID: 26535528]
[13]
Arnán Sangerman, M.; Fernández Moreno, A.; García Quintana, A.; García-Vidal, C.; Olave Rubio, M.T.; Del Mar Tormo Díaz, M.; Vendranas, M.; Rodriguez Macias, G. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Expert Rev. Hematol., 2022, 15(3), 203-214.
[http://dx.doi.org/10.1080/17474086.2022.2054801] [PMID: 35332831]
[14]
Cerchione, C.; Peleteiro Raíndo, A.; Mosquera Orgueira, A.; Mosquera Torre, A.; Bao Pérez, L.; Marconi, G.; Isidori, A.; Pérez Encinas, M.M.; Martinelli, G. Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Expert Rev. Hematol., 2021, 14(9), 851-865.
[http://dx.doi.org/10.1080/17474086.2021.1969911] [PMID: 34424108]
[15]
Roboz, G.J.; Strickland, S.A.; Litzow, M.R.; Dalovisio, A.; Perl, A.E.; Bonifacio, G.; Haines, K.; Barbera, A.; Purkayastha, D.; Sweet, K. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: The RADIUS-X expanded access program. Leuk. Lymphoma, 2020, 61(13), 3146-3153.
[http://dx.doi.org/10.1080/10428194.2020.1805109] [PMID: 32812818]
[16]
Men, Y.; Hu, Z.; Dong, J.; Xu, X.; Tang, B. Formal [1 + 2 + 3] annulation: Domino access to carbazoles and indolocarbazole alkaloids. Org. Lett., 2018, 20(17), 5348-5352.
[http://dx.doi.org/10.1021/acs.orglett.8b02266] [PMID: 30110173]
[17]
Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett., 1999, 40(6), 1109-1112.
[http://dx.doi.org/10.1016/S0040-4039(98)02594-5]
[18]
Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. A new, efficient method for the synthesis of bisindolylmaleimides. J. Org. Chem., 1998, 63(17), 6053-6058.
[http://dx.doi.org/10.1021/jo980513c] [PMID: 11672217]
[19]
Zhang, D.; Wang, G.; Yu, X.; Wei, T.; Farbiak, L.; Johnson, L.T.; Taylor, A.M.; Xu, J.; Hong, Y.; Zhu, H.; Siegwart, D.J. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol., 2022, 17(7), 777-787.
[http://dx.doi.org/10.1038/s41565-022-01122-3] [PMID: 35551240]
[20]
Zhou, Z.; Liu, Y.; Jiang, X.; Zheng, C.; Luo, W.; Xiang, X.; Qi, X.; Shen, J. Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy. Int. J. Biol. Macromol., 2023, 224, 797-809.
[http://dx.doi.org/10.1016/j.ijbiomac.2022.10.167] [PMID: 36283555]
[21]
Zhen, C.; Luo, W.; Liu, Y.; Chen, J.; Deng, H.; Zhou, Z.; Shen, J. Killing three birds with one stone: Multi-stage metabolic regulation mediated by clinically usable berberine liposome to overcome photodynamic immunotherapy resistance. Chem. Eng. J., 2023, 454(2), 140164.
[http://dx.doi.org/10.1016/j.cej.2022.140164]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy